PXD053548

PXD053548 is an original dataset announced via ProteomeXchange.

Title	Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells
Description	Patient-derived secondary AML cells were treated with 100 nM of SY-5609 for 24 hours, 100 nM of FHD-286 for 48 hours, or 20 µM of Tasquinimod for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and lethal effects of treatment with a CDK7 inhibitor, chromatin remodeling inhibitor, or S100A8/S100A9 inhibitor or in secondary AML cells. Patient-derived de novo AML cells with MLL1 rearrangement and Menin T349M mutation were treated with 100 nM of FHD-286 or 500 nM SNDX-50469 for 48 hours to determine the global protein expression alterations that correlate with the cell cycle, growth inhibitory and/or lethal effects of treatment with a chromatin remodeling inhibitor, FHD-286, or a Menin inhibitor SNDX-50469 in MLL1 rearranged AML cells
HostingRepository	PRIDE
AnnounceDate	2025-04-28
AnnouncementXML	Submission_2025-04-28_12:42:56.474.xml
DigitalObjectIdentifier
ReviewLevel	Peer-reviewed dataset
DatasetOrigin	Original dataset
RepositorySupport	Unsupported dataset by repository
PrimarySubmitter	Antrix Jain
SpeciesList	scientific name: Homo sapiens (Human); NCBI TaxID: 9606;
ModificationList	No PTMs are included in the dataset
Instrument	Orbitrap Exploris 480

Revision	Datetime	Status	ChangeLog Entry
0	2024-07-01 21:19:19	ID requested
⏵ 1	2025-04-28 12:42:57	announced

10.1182/blood.2024026388;

Fiskus W, Mill CP, Bose P, Masarova L, Pemmaraju N, Dunbar A, Birdwell CE, Davis JA, Das K, Hou H, Manshouri T, Jain A, Malovannaya A, Philip K, Alhamadani N, Matthews A, Lin K, Flores LB, Loghavi S, DiNardo C, Su X, Rampal RK, Bhalla KN, Preclinical efficacy of CDK7 inhibitor-based combinations against myeloproliferative neoplasms transformed to AML. Blood, 145(6):612-624(2025) [pubmed]

submitter keyword: Secondary AML, SNDX-50469, Tasquinimod, CDK7 inhibitor, FHD-286

Kapil N. Bhalla
contact affiliation	Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
contact email	kbhalla@mdanderson.org
lab head
Antrix Jain
contact affiliation	Baylor College of Medicine
contact email	antrixj@bcm.edu
dataset submitter

Dataset FTP location NOTE: Most web browsers have now discontinued native support for FTP access within the browser window. But you can usually install another FTP app (we recommend FileZilla) and configure your browser to launch the external application when you click on this FTP link. Or otherwise, launch an app that supports FTP (like FileZilla) and use this address: ftp://ftp.pride.ebi.ac.uk/pride/data/archive/2025/04/PXD053548

PRIDE project URI

• PRIDE
  1. PXD053548
     1. Label: PRIDE project
     2. Name: Effect of CDK7 inhibitor, FHD-286, SNDX-50469, or Tasquinimod on protein expression alterations in patient-derived secondary AML or de novo MLL1-rearranged AML cells